Lumito Arrow right Arrow right

Financial overview

Third quarter, January–September 2021

  • Net sales amounted to KSEK 0 (0).
  • Result after taxes amounted to KSEK -19,517 (-10,848).
  • Basic and diluted earnings per share amounted to SEK -0.22 (-0.15).
  • Cash flow from operating activities after change in working capital amounted to KSEK -19,927 (-12,239).
  • Cash and cash equivalents amounted to KSEK 10,307 (4,191) on the balance sheet date.

July–September 2021

  • Net sales amounted to KSEK 0 (0).
  • Result after taxes amounted to KSEK -6,073 (-3,851).
  • Basic and diluted earnings per share amounted to SEK -0.07 (-0.05).
  • Cash flow from operating activities after change in working capital amounted to KSEK -7,045 (-6,745).

Significant events in the third quarter

  • The Company convened an extraordinary general meeting, which resolved to implement a long-term incentive scheme for Mattias Lundin, CEO of the Company, including a directed issue of no more than 1,000,000 warrants. The incentive scheme aims to promote an increased commonality of interest in the long term between the CEO and the Company’s shareholders.
  • The basic patent was granted in Europe. Lumito’s basic patent, a patent in the first patent family protecting the use of upconverting nanoparticles (UCNPs) for imaging in scattering materials such as human tissue, was approved also in Brazil.

Significant events after the quarter

  • TTP plc delivered the next version of Lumito’s scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, a greater capacity to test new indications and complete the evaluation of the breast cancer marker Her2.
  • Lumito AB entered into an agreement with Mangold Fondkommission AB to act as the company’s mentor in trading on NGM Nordic SME. Mangold Fondkommission took over as mentor on 15 October 2021.
  • The Board of Directors decided to bring forward the Company’s report for the third quarter of 2021 to 20 October 2021.